Vir Biotechnology Inc
$ 9.50
-3.36%
10 Apr - close price
- Market Cap 1,518,208,000 USD
- Current Price $ 9.50
- High / Low $ 9.90 / 9.41
- Stock P/E N/A
- Book Value 5.49
- EPS -3.05
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.46 %
- 52 Week High 10.94
- 52 Week Low 4.16
About
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
Analyst Target Price
$20.78
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-23 | 2025-11-05 | 2025-07-30 | 2025-04-30 | 2025-02-20 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.31 | -1.17 | -0.8 | -0.88 | -0.76 | -1.56 | -1.02 | -0.48 | -0.86 | -1.22 | -1.45 | -1.06 |
| Estimated EPS | -0.54 | -0.84 | -0.7754 | -0.8433 | -0.89 | -1.05 | -0.9 | -1.05 | -1.01 | -1.21 | -1.2 | -0.87 |
| Surprise | 0.23 | -0.33 | -0.0246 | -0.0367 | 0.13 | -0.51 | -0.12 | 0.57 | 0.15 | -0.01 | -0.25 | -0.19 |
| Surprise Percentage | 42.5926% | -39.2857% | -3.1726% | -4.352% | 14.6067% | -48.5714% | -13.3333% | 54.2857% | 14.8515% | -0.8264% | -20.8333% | -21.8391% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.01 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VIR
2026-04-10 21:09:34
Vir Biotechnology announced that its Chief Medical Officer, Mark Eisner, will be stepping down on April 24, 2026. The company has initiated a search for his successor to manage leadership transition in its clinical and medical organization. Analysts currently rate VIR stock as a Hold with a $9.50 price target, while Spark's AI Analyst gives it a Neutral score due to weak financials partially offset by strong earnings-call fundamentals.
2026-04-10 20:01:20
Vir Biotechnology announced that its Executive Vice President and Chief Medical Officer, Mark Eisner, MD, MPH, will step down from his role effective April 24, 2026. The company has initiated a search for his successor to oversee its clinical and medical strategy. This leadership change was reported as an 8-K filing to the SEC.
2026-04-10 16:40:20
This page provides access to Vir Biotechnology (VIR) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, with AI-generated summaries and sentiment analysis. Recent filings detail insider stock sales, equity awards, and tax-withholding transactions by executives like CEO Marianne De Backer and CFO Jason O'Byrne. The filings also cover significant company events such as licensing agreements and clinical trial updates.
2026-04-09 07:13:55
Aberdeen Group plc reduced its stake in Vir Biotechnology, Inc. by 8.9% in the fourth quarter, selling 135,688 shares and retaining 1.39 million shares. Despite this, Vir Biotechnology exceeded quarterly earnings and revenue expectations, and equity analysts generally maintain a "Moderate Buy" rating with a consensus target price of $20.44. Insider selling has also occurred, with executives selling over 257,000 shares in the past three months.
2026-04-08 08:10:03
Brokerages have given Vir Biotechnology, Inc. (NASDAQ:VIR) an average recommendation of "Moderate Buy," with an average one-year price target of $20.44 among ten analysts. Insiders have sold shares totaling $2.33 million over the last three months, while institutional investors like ARCH Venture and GSK have established significant new stakes. The company recently surpassed quarterly earnings and revenue expectations but remains unprofitable, with analysts projecting negative EPS for the current year.
2026-04-07 22:41:17
Vir Biotechnology CEO Backer Marianne De sold 72,559 shares of the company's stock on April 6th at an average price of $9.16, totaling approximately $664,640.44. This transaction, executed under a Rule 10b5-1 plan, was to cover tax withholding on vested equity, reducing her ownership by 7.11% to 948,145 shares. The company recently beat quarterly earnings expectations and holds a "Moderate Buy" consensus rating from analysts with an average price target of $20.44.
